U.S. COMPANY FILING
BIOGEN INC. — Form 10-Q filed 2026-04-29
Filing text preview
Biogen's Q1 2026 revenue rose 2% to $2.48B, net income up 33% to $319.5M, EPS $2.17. R&D expenses increased 24% due to late-stage programs. Acquired TJ Biopharma's felzartamab rights in Greater China for $100M upfront. Faces uncertainties from US tariffs and IRA drug pricing reforms.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record